Ciprofibrate
Ciprofibrate
CLINICAL USE
Hyperlipidaemia
DOSE IN NORMAL RENAL FUNCTION
100 mg daily
PHARMACOKINETICS
Molecular weight                           :289.2 %Protein binding                           :95–99 %Excreted unchanged in urine     : 20–25 Volume of distribution (L/kg)       :12 litreshalf-life – normal/ESRD (hrs)      :38–86/171.9 DOSE IN RENAL IMPAIRMENT
GFR (mL/MIN)
20 to 50     : Dose as in normal renal function 10 to 20     : 100 mg every 48 hours <10           : Avoid. See ‘Other Information’ DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES
CAPD                :Not dialysed. Avoid HD                     :Not dialysed. AvoidHDF/high flux   :Unknown dialysability. AvoidCAV/VVHD      :Unknown dialysability. Dose as in GFR 10 to 20 mL/min IMPORTANT DRUG INTERACTIONS
Potentially hazardous interactions with other drugsAntibacterials: increased risk of myopathy with daptomycin – try to avoid concomitant useAnticoagulants: enhances effect of coumarins and phenindione. Dose of anticoagulant should be reduced by up to 50% and readjusted by monitoring INRAntidiabetics: may improve glucose tolerance and have an additive effect with insulin or sulphonylureasLipid-regulating drugs: increased risk of myopathy in combination with statins (do not exceed 10 mg of simvastatin1) and ezetimibe – avoid concomitant use with ezetimibe ADMINISTRATION
Reconstition
– Route
Oral Rate of Administration
–Comments
– OTHER INFORMATION
Increased risk of rhabdomyolysis in doses of 200 mg or greaterApproximately 30–75% of a single dose administered to volunteers was excreted in the urine in 72 hours, either as unchanged ciprofibrate (20–25% of the total excreted) or as a conjugate. Subjects with moderate renal impairment excreted on average 7% of a single dose as unchanged ciprofibrate over 96 hours, compared with 6.9% in normal subjects. In subjects with severe insufficiency this was reduced to 4.7%
See how to identify renal failure stages according to GFR calculation
See how to diagnose irreversible renal disease
Home